The stock of Theriva Biologics Inc (AMEX: TOVX) has decreased by -17.62 when compared to last closing price of 0.64.Despite this, the company has seen a loss of -61.60% in its stock price over the last five trading days. globenewswire.com reported 2025-05-08 that ROCKVILLE, Md., May 08, 2025 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the closing of its previously announced “reasonable best efforts” public offering of 6,818,180 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 6,818,180 shares of common stock at a combined offering price of $1.10 per share and accompanying warrant (the “Offering”). The Company received aggregate gross proceeds of approximately $7.5 million, before deducting placement agent fees and other offering expenses, and assuming no exercise of the warrants. The warrants have an exercise price of $1.10 per share, became exercisable immediately upon issuance and expire five years from the issuance date.
Is It Worth Investing in Theriva Biologics Inc (AMEX: TOVX) Right Now?
Company’s 36-month beta value is 1.09.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TOVX is 2.75M, and currently, short sellers hold a 2.69% ratio of that floaft. The average trading volume of TOVX on May 12, 2025 was 802.90K shares.
TOVX’s Market Performance
TOVX stock saw a decrease of -61.60% in the past week, with a monthly decline of -49.53% and a quarterly a decrease of -62.68%. The volatility ratio for the week is 34.30%, and the volatility levels for the last 30 days are 15.36% for Theriva Biologics Inc (TOVX). The simple moving average for the past 20 days is -58.12% for TOVX’s stock, with a -74.77% simple moving average for the past 200 days.
TOVX Trading at -57.01% from the 50-Day Moving Average
After a stumble in the market that brought TOVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.68% of loss for the given period.
Volatility was left at 15.36%, however, over the last 30 days, the volatility rate increased by 34.30%, as shares sank -54.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -62.15% lower at present.
During the last 5 trading sessions, TOVX fell by -61.60%, which changed the moving average for the period of 200-days by -92.35% in comparison to the 20-day moving average, which settled at $1.2652. In addition, Theriva Biologics Inc saw -69.72% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TOVX
Current profitability levels for the company are sitting at:
- -171.08 for the present operating margin
The net margin for Theriva Biologics Inc stands at -166.58. The total capital return value is set at -0.95. Equity return is now at value -87.31, with -51.34 for asset returns.
Based on Theriva Biologics Inc (TOVX), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -10.82.
Currently, EBITDA for the company is -25.52 million with net debt to EBITDA at 0.51. When we switch over and look at the enterprise to sales, we see a ratio of -55.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.15.
Conclusion
In a nutshell, Theriva Biologics Inc (TOVX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
